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Abstract
Objectives: To assess the differences between normal and cirrhotic livers by means of T1 mapping of liver
parenchyma on gadoxetic acid (Gd-EOB-DTPA)-enhanced 3 Tesla (3T) MR imaging (MRI).
Methods: 162 patients with normal (n = 96) and cirrhotic livers (n = 66; Child-Pugh class A, n = 30; B, n = 28; C, n =
8) underwent Gd-EOB-DTPA-enhanced 3T MRI. To obtain T1 maps, two TurboFLASH sequences (TI = 400 ms and
1000 ms) before and 20 min after Gd-EOB-DTPA administration were acquired. T1 relaxation times of the liver and
the reduction rate between pre- and post-contrast enhancement images were measured.
Results: The T1 relaxation times for Gd-EOB-DTPA-enhanced MRI showed significant differences between patients
with normal liver function and patients with Child-Pugh class A, B, and C (p < 0.001). The T1 relaxation times showed
a constant significant increase from Child-Pugh class A up to class C (Child-Pugh class A, 335 ms ± 80 ms; B, 431
ms ± 75 ms; C, 557 ms ± 99 ms; Child-Pugh A to B, p < 0.001; Child-Pugh A to C, p < 0.001; Child-Pugh B to C, p <
0.001) and a constant decrease of the reduction rate of T1 relaxation times (Child-Pugh class A, 57.1% ± 8.8%; B,
44.3% ± 10.2%, C, 29.9% ± 6.9%; Child-Pugh A to B, p < 0.001; Child-Pugh A to C,p < 0.001; Child-Pugh B to C, p <
0.001).
Conclusion: Gd-EOB-DTPA-enhanced T1 mapping of the liver parenchyma may present a useful method for
determining severity of liver cirrhosis.
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Introduction
Cirrhosis, the final stage of chronic diffuse liver disease, is
histologically defined as the presence of regenerative nodules
surrounded by fibrous bands in response to chronic liver injury,
resulting in the distortion of the hepatic vasculature and
consecutive portal hypertension [1]. Numerous antifibrotic
agents are currently developed that may delay progression to
decompensated cirrhosis or even reverse cirrhosis; however,
progress has been impeded by the low number of methods
available for measuring the progression or reversal of fibrosis
[2].
The presence of hepatitis-related fibrosis is an indication for
antiviral treatment, and the presence of cirrhosis is an
indication for the specific monitoring of complications related to
portal hypertension and the increased risk of hepatocellular
carcinoma. Thus, the early detection of hepatic fibrosis and
cirrhosis has important clinical implications. In clinical routine,
determination of the severity of liver injury and the requirement
of antiviral therapy is often based on the histology of the liver
parenchyma [3,4].
Biopsy is thus considered the gold standard for the
diagnosing and staging of cirrhosis. The risk of disease
progression can be monitored by the sequential histological
grading of inflammation as well as by the staging of fibrosis [2].
However, liver biopsy is poorly accepted by patients and has a
risk of various complications, such as hemorrhage and
infection. In addition, liver biopsies may be prone to sampling
errors and inter-observer variability due to subjective
morphological evaluation [5,6]. Therefore, non-invasive
quantitative markers or diagnostic tests are required to assess
the presence and severity of liver cirrhosis. Several non-
invasive diagnostic methods for fibrosis or cirrhosis have been
evaluated. These methods mainly include either clinical signs,
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ultrasonographic signs, or biochemical blood parameters [7].
The recent advent of ultrasound-based imaging of tissue
elasticity, such as acoustic radiation force impulse (ARFI)
elastography, represents a non-invasive way to quantify liver
fibrosis. However, ARFI measurements have only limited intra-
and interoperator reproducibility [8].
Gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid
(Gd-EOB-DTPA) is a hepatocyte-specific contrast agent for
MRI of the liver (Bayer Schering Pharma, Berlin, Germany).
The additional value of Gd-EOB-DTPA compared with other
gadolinium-based contrast agents is the selective uptake of the
contrast medium by functioning hepatocytes. In turn, this
uptake can be used to acquire MR images during the
hepatobiliary phase (HP), which occurs approximately 15 to 20
min after the injection of the contrast medium [9]. Therefore,
this agent can be used for dynamic bolus phase MRI as well as
for liver-specific (hepatocyte-phase) MRI within the same
examination within a reasonable time frame, thus combining
the properties of an extracellular and a hepatocyte-specific
contrast agent [10]. As a result of the organic anion-
transporting polypeptide-1 (OATP1) dependent intracellular
uptake of Gd-EOB-DTPA and its T1-shortening effect,
functioning areas of the liver parenchyma exhibit T1
shortening. Furthermore, livers with normal hepatocyte function
show increased signal intensity during the HP, indicating that
the use of Gd-EOB-DTPA has the potential to directly measure
liver function [11,12].
Assessment of hepatic functional reserve plays a crucial role
in selecting therapeutic approaches in patients with liver tumors
as well as in preventing hepatic failure after treatment,
particularly in patients with chronic liver disease. The Child-
Pugh Score is commonly used to determine the prognosis of
chronic liver disease, such as liver cirrhosis.
Thus, the purpose of our study was to evaluate the
usefulness of Gd-EOB-DTPA-enhanced MRI in diagnosing
hepatic cirrhosis, to distinguish between different types of
cirrhosis, and to evaluate liver function using the T1 relaxation
time of liver parenchyma.
Materials and Methods
Patients
Between April 2012 and April 2013, 216 consecutive patients
with known liver cirrhosis, suspected chronic liver disease or
suspicious focal hepatic lesions detected during previous
ultrasonography or computed tomography examinations
underwent liver MRI including T1 mapping in our department.
54 patients were excluded from the analysis, because they had
either received a liver transplant (n = 7) or previous local
treatment for liver disease (n = 36), or their images had severe
motion artifacts due to a poor breath-holding technique (n =
11).
Finally, 162 patients were enrolled into our study: 96 patients
with normal liver function (31 women and 65 men; mean age,
59.2 years) and 66 patients with liver cirrhosis (15 women and
51 men; mean age, 60.4 years). The non-cirrhotic liver group
was chosen among patients with normal liver laboratory values
and without direct or indirect signs (e.g. splenomegaly) of liver
disease in ultrasound. Diagnosis of liver cirrhosis was based on
laboratory values, imaging findings and clinical findings
according to the Child-Pugh Score depending on the degree of
ascites (1 point, none; 2 points, mild; 3 points, moderate to
severe), serum bilirubin (mg/dl, 1 point, < 2; 2 points, 2 - 3; 3
points, > 3), serum albumin (g/dl, 1 point, < 3.5; 2 points, 2.8 -
3.5; 3 points, < 2.8), prothrombin time (INR, 1 point, < 1.7; 2
points, 1.71- 2.3; 3 points, > 2.3), and encephalopathy (1 point,
none; 2 points, Grade I-II; 3 points, Grade III- IV). 30 patients of
the 66 patients with liver cirrhosis were classified with Child-
Pugh A (LCA, 5 - 6 points), 28 patients with Child-Pugh B
(LCB, 7 - 9 points), and 8 patients with Child-Pugh C (LCC, 10
- 15 points). Patient characteristics are shown in Table 1.
Ethics statement
This prospective study was approved by the Institutional
Review Board of the University of Regensburg. Written
informed consent was obtained from all patients.
MR imaging protocol
All MRI examinations were conducted with a clinical 3T
whole body system (Magnetom Skyra, Siemens Healthcare,
Erlangen, Germany). For signal reception, a combination of
body and spine array coil elements (3T; 18-channel body
matrix coil, 24-channel spine matrix coil) was used in all
examinations.
At first, coronal respiratory-triggered single-shot T2-weighted
turbo spin-echo imaging was performed followed by breath-
hold transverse fast-spoiled gradient-echo images, i.e. T1-
weighted in-phase and T1-weighted out-of-phase imaging.
Then, a transverse T1-weighted volume interpolated breath
hold examination (VIBE) sequence with fat suppression was
acquired before contrast media injection and during dynamic
phases in arterial phase (20 s), late arterial phase (50 s) and
portal venous phase (80 s). All patients received a body weight
adapted dose of Gd-EOB-DTPA (0.025mmol/kg body weight)
administered via bolus injection with a flow rate of 1 mL/s,
flushed with 20 mL NaCl. Also axial respiratory-triggered
single-shot T2-weighted turbo spin-echo images, respiratory-
triggered BLADE sequence with fat suppression and diffusion
weighted images were acquired. Finally, transverse and
Table 1. Patient characteristics.
Group All (n=162) NLF (n = 96) LCA (n = 30) LCB (n = 28) LCC(n = 8)
Age 59.7 ± 12.2 59.2 ± 12.8 62.1 ± 11.0 59.8 ± 12.4 56.1 ± 8.3
Gender      
male 116 (72%) 65 (68%) 22 (73%) 25 (89%) 4 (50%)
female 46 (28%) 31 (32%) 8 (27%) 3 (11%) 4 (50%)
Height 1.73 ± 0.09 1.72 ± 0,1 1.73 ± 0.08 1.75 ± 0.08 1.72 ± 0.1
Weight 82.1 ± 17.9 80.0 ± 16.0 85.9 ± 19.3 87.3 ± 19.7 75.9 ± 23.4
BMI 27.4 ± 5.5 26.9 ± 5.0 28.6 ± 6.5 28.6 ± 6.5 25.7 ± 7.8
Values indicate mean ± standard deviation.
NLF: normal liver function; LCA: liver cirrhosis Child-Pugh A; LCB: liver cirrhosis
Child-Pugh B; LCC: liver cirrhosis Child-Pugh C; BMI: body mass index
doi: 10.1371/journal.pone.0085658.t001
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coronal breath-hold T1-weighted VIBE sequence was repeated
in hepatobiliary phase 20 min after contrast media
administration.
In addition to the routine MRI protocol, two TurboFLASH
sequences (inversion time (TI), 400 ms, 1000 ms; repetition
time (TR), 4000 ms; echo time (TE), 1.16 ms; flip angle 8°;
slice thickness, 6 mm; FOV 400 mm x 400 mm; matrix size,
192 x 192; acquisition time 16s) were acquired to obtain T1
maps of the porta hepatis in a single breath-hold before and 20
min after Gd-EOB-DTPA administration.
Image analysis
The T1 maps of the liver were generated with the evaluation
tool for calculating T1 relaxation times (Siemens Healthcare,
Erlangen, Germany).
In T1 mapping images before and after the administration of
the contrast medium, regions of interest (ROIs) were located
with reasonable care in the right lobe (2 ROIs) and in the left
lobe (1 ROI). We avoided focal hepatic lesions (e.g.
hepatocellular carcinoma, hemangioma, cysts, etc.), imaging
artifacts, and major branches of the portal or hepatic veins.
Each ROI was a circle (size of the ROI ranged between 1.0
cm2 and 3.5 cm2) chosen as large as possible. Mean T1 values
for the three ROIs were considered as the representative T1
value for the liver. ROIs of identical size and shape were
placed at the same imaging sequence in T1 maps before and
after Gd-EOB-DTPA administration. The reduction rate in T1
values between pre- and post-Gd-EOB-DTPA enhancement
was calculated as follows:
Reduction rate of T1 values = T1pre−T1postT1pre ×100 %
T1pre is the T1 relaxation time before Gd-EOB-DTPA
administration and T1post the T1 relaxation time 20 min after
Gd-EOB-DTPA administration. T1 maps were color-coded
using a visualization tool of the open source OsiriX imaging
software.
Statistical analysis
Data are expressed as mean ± standard deviation (SD). A
one-way analysis of variance (ANOVA) was used to analyze
differences between patients with normal liver function and
patients with liver cirrhosis. Post hoc pair-wise comparisons
were made with the Tukey procedure. ROC analyses were
done to differentiate between patient groups, and the optimal
cut-off was estimated according to the Youden Index.
Estimates for the area under the curve (AUC) as well as true
classification rates are reported. All tests were two-sided and
values of p < 0.05 indicated a significant difference. All
statistical analyses were done with IBM SPSS Statistics
(version 20, Chicago, IL) and R 2.14.
Results
Including the results of all patients, the T1 relaxation times of
non-enhanced MRI (774.2 ms ± 123 ms) and Gd-EOB-DTPA-
enhanced MRI (322.3 ms ± 113 ms) were significantly different
(p < 0.001): the mean reduction rate was 58.3% ± 13%.
The pre-contrast T1 relaxation time of the liver parenchyma
showed no significant difference between patients with normal
liver function (NLF) and patients with LCA, LCB, and LCC (NFL
to LCA, p = 0.90, 95% CI (-84.67 to 49.25); NFL to LCB, p =
0.90, 95% CI (-86.88 to 50.64); NLF to LCC; p = 0.97, 95% CI
(-138.64 to 96.98)). After the administration of Gd-EOB-DTPA,
T1 relaxation times decreased significantly between patients
with normal liver function and patients classified according to
the Child-Pugh system (p < 0.001), (Figure 1A, Table 2).
A comparison between patients with normal liver function
and patients with liver cirrhosis stratified by the Child-Pugh
classification showed that T1 relaxation times were prolonged
in case of cirrhosis: The T1 relaxation times showed a constant
significant increase from the NLF group to the LCC group (NFL
to LCA, p < 0.001, 95% CI (-111.40 to -26.71); NFL to LCB, p <
0.001, 95% CI (-208.59 to -121.62); NLF to LCC; p < 0.001,
95% CI (-365.34 to -216.34)), (Figure 1B).
20 min after contrast medium administration, reduction rates
of T1 relaxation times were significantly lower for patients with
liver cirrhosis compared to patients with NLF (p ≤ 0.001). A
constant significant decrease of the reduction rate of T1
relaxation times could be shown (NFL to LCA, p < 0.001, 95%
CI (0.04 to 0.12); NFL to LCB, p < 0.001, 95% CI (0.16 to 0.25);
NLF to LCC; p < 0.001, 95% CI (0.28 to 0.44)), (Figure 2, Table
3).
Color-coded T1 relaxation times on T1 mapping images from
the NLF group to the LCC group on pre- and post-contrast
MRI, respectively, are shown in Figure 3.
An ROC analysis was done with regard to cut-off values and
area under the curve (AUC) values for differentiating patients
with NLF from patients with liver cirrhosis as well as for
differentiating different grades of cirrhosis based on the
reduction rates. The cut-off value of T1 relaxation times to
distinguish the NLF group from the liver cirrhosis groups LCA,
LCB, and LCC were 419.8 ms, 389.1 ms, and 326.3 ms,
respectively. The cut-off value to differentiate LCB from LCA
and LCC was 329.5 ms and 325.5 ms. The cut-off values
regarding the reduction rate of T1 relaxation times to
differentiate the NLF group from the liver cirrhosis groups LCA,
LCB, and LCC were 63.5%, 59.1%, and 40.9%, respectively.
The cut-off values to differentiate LCB from LCA and LCC were
41.2% and 38.1%. Various cut-off values of T1 relaxation times
and reduction rates, each with corresponding AUC values and
true classification rates are shown in Table 4 and Table 5.
Discussion
Gd-EOB-DTPA is a liver-specific MRI contrast agent with
combined dynamic perfusion and hepatocyte selective
properties [13]. After intravenous injection, gadoxetate
disodium is gradually taken up by hepatocytes. Approximately
50% of the agent is eventually excreted via the biliary pathway,
whereas the percentage of the contrast medium not eliminated
by the hepatobiliary system is cleared by glomerular filtration in
the kidneys. Peak liver signal intensity has been observed
during the hepatobiliary phase 20 min after contrast medium
Assessment of Liver Cirrhosis Using T1 Mapping
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Figure 1.  Pre- and post-contrast T1 relaxation times.  (A) Boxplots indicating T1 relaxation times before (pre) and after (post)
Gd-EOB-DTPA administration in patients with normal liver function and in patients with liver cirrhosis Child-Pugh A, Child-Pugh B,
and Child-Pugh C. After contrast medium administration, T1 relaxation times were significantly reduced in each group.
(B) Boxplots indicating T1 relaxation times after Gd-EOB-DTPA administration in patients with normal liver function and in patients
with liver cirrhosis Child-Pugh A, Child-Pugh B, and Child-Pugh C. T1 relaxation times increased significantly with increased
progression of liver cirrhosis.
NLF: normal liver function; LCA: liver cirrhosis Child-Pugh A; LCB: liver cirrhosis Child-Pugh B; LCC: liver cirrhosis Child-Pugh C.
Data given as mean T1 reduction rate ± standard deviation. Tukey’s adjustment was used to generate Boxplots, and the Wilcoxon-
Test was used to compare groups.
***p ≤ 0.001, ** ≤ 0.01.
doi: 10.1371/journal.pone.0085658.g001
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injection, followed by a plateau-like enhancement lasting for
about 2 h [9,14]. The hepatocyte-specific uptake of Gd-EOB-
DTPA is thought to be mediated by active membrane transport
systems, such as OATP1, located at the sinusoidal membrane,
and the multidrug resistance protein 2 (MRP2), located at the
Table 2. T1 relaxation times of the liver in non-enhanced
and Gd-EOB-DTPA-enhanced MRI.
 non-enhanced (ms) Gd-EOB-DTPA- enhanced (ms)
NLF 767 ± 129 267 ± 76
LCA 784 ± 110 335 ± 80
LCB 784 ± 114 431 ± 75
LCC 788 ± 123 557 ± 99
Values indicate mean ± standard deviation.
NLF: normal liver function; LCA: liver cirrhosis Child-Pugh A; LCB: liver cirrhosis
Child-Pugh B; LCC: liver cirrhosis Child-Pugh C
doi: 10.1371/journal.pone.0085658.t002
canalicular membrane of hepatocytes [15]. There is some
evidence that Gd-EOB-DTPA-enhanced MRI may assess liver
function.
In cirrhotic livers, hepatocyte function is impaired compared
to that in non-cirrhotic livers. Cirrhotic liver parenchyma has
Table 3. Reduction rates of T1 relaxation times of the liver
in non-enhanced and Gd-EOB-DTPA-enhanced MRI.
 Reduction rates of T1 relaxation time (%)
NLF 65.1 ± 7.1
LCA 57.1 ± 8.8
LCB 44.3 ± 10.2
LCC 29.9 ± 6.9
Values indicate mean ± standard deviation.
NLF: normal liver function; LCA: liver cirrhosis Child-Pugh A; LCB: liver cirrhosis
Child-Pugh B; LCC: liver cirrhosis Child-Pugh C
doi: 10.1371/journal.pone.0085658.t003
Figure 2.  Reduction rates of T1 relaxation times.  Boxplots of reduction rates of T1 relaxation times of the liver in patients with
normal liver function and in patients with liver cirrhosis classified as Child-Pugh A, Child-Pugh B, and Child-Pugh C. Reduction rates
were significantly reduced with increasing progression of liver cirrhosis.
NLF: normal liver function; LCA: liver cirrhosis Child-Pugh A; LCB: liver cirrhosis Child-Pugh B; LCC: liver cirrhosis Child-Pugh C.
Data given as mean T1 reduction rate ± standard deviation. Tukey’s adjustment was used to generate Boxplots, and the Wilcoxon-
Test was used to compare groups.
***p ≤ 0.001.
doi: 10.1371/journal.pone.0085658.g002
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Figure 3.  T1 relaxation times of the liver on T1 mapping
color-coded images.  A - H, T1 mapping images calculated
from 2 TurboFlash sequences (TI = 400 ms and 1000 ms) were
obtained before (A, C, E, G) and 20 min after Gd-EOB-DTPA
administration (B, D, F, H) in a patient with normal liver function
(A, B) and patients with liver cirrhosis Child-Pugh A (C, D),
Child-Pugh B (E, F), and Child-Pugh C (G, H). The mean T1
relaxation times of liver parenchyma were as follows: 755.6 ms
(A), 211.9 ms (B), 717.1 ms (C), 316.0 ms (D), 760.5 ms (E),
434.0 ms (F), 705.7 ms (G) and 482.4 ms (H). The reduction
rate of T1 relaxation times in patients with normal liver function
and patients with liver cirrhosis Child-Pugh A, Child-Pugh B,
and Child-Pugh C were 72%, 56%, 43%, and 32%,
respectively. In patients with normal liver function, T1 relaxation
times on T1 mapping color-coded images of the liver on post-
contrast MRI (B) showed a markedly darker color distribution of
the liver parenchyma than that on the pre-contrast mapping
image (A), indicating a strong Gd-EOB-DTPA-induced
shortening of T1 relaxation time 20 min after contrast medium
administration. With increased progression of liver cirrhosis, the
color distribution in the liver parenchyma could be visually
confirmed to show less change on post-contrast T1- mapping
images.
doi: 10.1371/journal.pone.0085658.g003
shown reduced signal intensity in HB relative to non-cirrhotic
liver parenchyma with a correlation between hepatic
parenchymal enhancement and the Child-Pugh Score.
However, measurements of signal intensities describe relative
values, are easily affected by variable parameters, and involve
high standard deviations indicating huge variances [12,16,17].
Gd-EOB-DTPA is a contrast medium with T1-shortening
effects [18]. Therefore, we generated T1 maps indicating the
absolute values of T1 relaxation times that did not considerably
vary at various points of measurement and thus led to low
values of standard deviation.
After administration of Gd-EOB-DTPA, patients with normal
liver function had the lowest values of T1 relaxation times (267
ms). These values showed a constant significant increase of
T1 relaxation times from patients with normal liver function up
to patients with Child-Pugh class C (LCA, 335 ms; LCB, 431
ms; LCC, 557 ms). However, shortening of T1 relaxation times
after contrast medium administration in non-cirrhotic livers and
prolonged post-contrast T1 relaxation times in cirrhotic livers
may be modified by pre-contrast T1 relaxation times. To
evaluate the actual intracellular uptake of Gd-EOB-DTPA, we
assessed the relative change in T1 relaxation times defined as
Table 4. ROC analysis indicating various cut-off values and
diagnostic performance to differentiate patients with NLF
from patients with liver cirrhosis LCA, LCB, and LCC: T1
relaxation times after Gd-EOB-DTPA administration.
 Cut-offs of T1 relaxation time (ms) AUC (true classification rates)
NLF - LCA 419.8 0.627 (80%, 43%)
NLF - LCB 389.2 0.834 (91%, 75%)
NLF - LCC 326.3 0.996 (98%, 100%)
LCA - LCB 329.5 0.971 (90%, 100%)
LCB - LCC 325.5 0.835 (64%, 100%)
AUC: area under the receiver operating characteristic curve; NLF: normal liver
function; LCA: liver cirrhosis Child-Pugh A; LCB: liver cirrhosis Child-Pugh B; LCC:
liver cirrhosis Child-Pugh C
doi: 10.1371/journal.pone.0085658.t004
Table 5. ROC analysis indicating various cut-off values and
diagnostic performance to differentiate patients with NLF
from patients with liver cirrhosis LCA, LCB, and LCC:
reduction rate of T1 relaxation between pre- and post-
contrast times.
 Cut-offs of reduction rate (%) AUC (true classification rates)
NLF - LCA 63.5 0.773 ( 67%, 80%)
NLF - LCB 59.1 0.962 ( 84%, 96%)
NLF - LCC 40.9 1.000 (100%, 100%)
LCA - LBB 41.2 0.996 ( 97%, 100%)
LCB - LCC 38.1 0.888 ( 79%, 100%)
AUC: area under the receiver operating characteristic curve; NLF: normal liver
function; LCA: liver cirrhosis Child-Pugh A; LCB: liver cirrhosis Child-Pugh B; LCC:
liver cirrhosis Child-Pugh C
doi: 10.1371/journal.pone.0085658.t005
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the reduction rate, which was 65.1% in non-cirrhotic patients.
This percentage was further decreased with increased
progression of liver cirrhosis (LCA, 57.1%; LCB, 44.3%, LCC,
29.9%). The reduced Gd-EOB-DTPA uptake may be either due
to a decreased number of normal hepatocytes according to
characteristic morphological changes in cirrhotic liver tissue or
due to a decreased Gd-EOB-DTPA uptake by hepatocytes,
attributed to diminished OATP1 activity, resulting in lower Gd-
EOB-DTPA intracellular hepatocyte uptake [19]. In animal
models, the expression of organic anion-transporting proteins
has been reported to decrease in hepatitis and cirrhosis and to
up-regulate MRP2 activity [20,21].
However, it is still uncertain whether morphologically
advanced cirrhosis would impair the uptake of Gd-EOB-DTPA
and, in turn, reduce liver parenchymal enhancement after Gd-
EOB-DTPA administration because of the expected impairment
of hepatocyte function or the decreased number of
hepatocytes. In this context, it has been reported that
decreased hepatic enhancement in patients with impaired
hepatocyte function may impede the detection of focal liver
lesions because of the reduced contrast between the lesion
and the surrounding liver parenchyma [22]. Therefore, the
detection of focal liver lesions in patients with impaired liver
function, such as severe cirrhosis, also represents a challenge
in daily clinical routine.
Because the intracellular uptake of Gd-EOB-DTPA
decreases with impaired liver function, measurement of T1
relaxation times in Gd-EOB-DTPA-enhanced images may be a
new, non-invasive technique to quantify the actual function of
hepatocytes.
In line with the controversial findings in the current literature
[23,24], we did not find any significant differences in T1
relaxation times between patients with normal liver function and
patients with liver cirrhosis in non-enhanced images (NLF: 767
ms ± 129 ms; LCA: 784 ms ± 110 ms; LCB: 784 ms ± 114 ms;
LCC, 788 ms ± 123 ms). Liver cirrhosis involves increased
deposition of manganese, copper, iron, and collagen ─
paramagnetic macromolecules that induce T1-shortening
effects [25,26]. However, characteristics of T1 relaxation times
in healthy and cirrhotic patients has been discussed
controversially in the literature: Contrary to our findings,
Thomson et al. indicated that tissue remodeling in liver
cirrhosis may be reflected in prolonged T1 relaxation times
[27], a conclusion that has been supported by other recent
studies [17,28]. These findings have been validated in some
recent animal studies that showed an increase in T1 relaxation
times in CCL4-induced liver fibrosis. However, this increase is
most likely caused by pathophysiological processes of induced
liver fibrogenesis characterized by edema, inflammation, and
synthesis of the extracellular matrix [29,30]. At this early stage
of fibrous formation, the tissue is often edematous because
new vessels have leaky interendothelial junctions, allowing the
passage of proteins and red blood cells into the extravascular
space [31]. This process results in augmented hepatic water
content, hypercellularity, and an increase in the ratio of free to
bound water with consecutive prolonged T1 relaxation times
[32,33]. However, increases of T1 relaxation times could also
be observed in a bile-duct ligation model, which is another
common method to induce liver fibrosis, resulting in minimal
inflammation and limited edema. Such increases are most
likely due to an increase in water-containing small biliary ducts
[34].
Advanced stages of cirrhosis show increased extracellular
constituents, mostly collagen, and a decreased number of
active fibroblasts and new vessels, resulting in lower total water
contents and consecutively decreased T1 relaxation times. In
the clinical setting, liver cirrhosis is mostly an expression of
chronic liver disease and is not commonly combined with acute
inflammation. Kim et al. have recently reported a significant
shortened T1 value in patients with liver cirrhosis measured by
means of an unenhanced 3T system [35]. These controversial
findings indicate that non-enhanced MRI is unlikely to be an
appropriate method for detecting and staging liver fibrosis.
Our study supports the conclusion that measuring T1
relaxation times by means of Gd-EOB-DTPA-enhanced MRI
may be incorporated into the clinical routine as a screening test
of liver imaging to detect silent disease and to define the stage
of existing disease or liver function in pre- or postoperative
assessments, while extending the acquisition time of a liver
MRI protocol by only 32 s.
Our study has several limitations. First, the trial was a single-
center study with a limited patient population. Second, our
study included various types of cirrhosis, such as cirrhosis
induced by alcohol, cirrhosis based on longtime viral hepatitis,
or a combination of both. Future studies should use a
homogenous patient population because the etiology of
cirrhosis has an impact on parenchymal changes and may thus
influence the resulting T1 maps.
Third, some evidence exists that clinical Child-Pugh scores
are related to histopathological fibrosis, and Child-Pugh
classification has been proven to correctly assess disease
stages in clinical practice. However, results of T1 mapping
needs to be evaluated in comparison to histopathological
results to prove that disease progression into higher Child-
Pugh classes also reflects progressive parenchymal changes.
Finally, we compared the hepatic intracellular uptake of Gd-
EOB-DTPA only with the Child-Pugh classification but did not
evaluate other liver function tests, such as ICG test. Therefore,
further studies are required in this respect.
In conclusion, T1 mapping by means of non-enhanced and
Gd-EOB-DTPA-enhanced MRI may provide suitable and robust
parameters for detecting and characterizing liver cirrhosis at an
early stage. Additionally, this method may be useful for
monitoring disease progression and has the potential to
become a novel index of global and remnant liver function.
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